角膜新生血管的当前和新兴治疗方法。
Current and emerging therapies for corneal neovascularization.
机构信息
Ocular Tissue Engineering Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA; Cincinnati Eye Institute, Edgewood, KY/ University of Cincinnati, Department of Ophthalmology, Cincinnati, OH, USA.
出版信息
Ocul Surf. 2018 Oct;16(4):398-414. doi: 10.1016/j.jtos.2018.06.004. Epub 2018 Jun 20.
Abstract
The cornea is unique because of its complete avascularity. Corneal neovascularization (CNV) can result from a variety of etiologies including contact lens wear; corneal infections; and ocular surface diseases due to inflammation, chemical injury, and limbal stem cell deficiency. Management is focused primarily on the etiology and pathophysiology causing the CNV and involves medical and surgical options. Because inflammation is a key factor in the pathophysiology of CNV, corticosteroids and other anti-inflammatory medications remain the mainstay of treatment. Anti-VEGF therapies are gaining popularity to prevent CNV in a number of etiologies. Surgical options including vessel occlusion and ocular surface reconstruction are other options depending on etiology and response to medical therapy. Future therapies should provide more effective treatment options for the management of CNV.
摘要
角膜的独特之处在于其完全无血管。角膜新生血管（CNV）可由多种病因引起，包括隐形眼镜佩戴、角膜感染和眼表疾病（炎症、化学伤和角膜缘干细胞缺乏等）。治疗主要针对引起 CNV 的病因和病理生理学，包括药物和手术治疗。由于炎症是 CNV 病理生理学的关键因素，皮质类固醇和其他抗炎药物仍然是治疗的主要方法。抗血管内皮生长因子（VEGF）治疗在多种病因中越来越受欢迎，可用于预防 CNV。手术治疗包括血管闭塞和眼表重建，具体取决于病因和对药物治疗的反应。未来的治疗方法应为 CNV 的管理提供更有效的治疗选择。
相似文献
1
Current and emerging therapies for corneal neovascularization.角膜新生血管的当前和新兴治疗方法。
Ocul Surf. 2018 Oct;16(4):398-414. doi: 10.1016/j.jtos.2018.06.004. Epub 2018 Jun 20.
2
Corneal neovascularization and biological therapy.角膜新生血管化与生物治疗。
J Med Life. 2015 Oct-Dec;8(4):444-8.
3
Early effects of dexamethasone and anti-VEGF therapy in an inflammatory corneal neovascularization model.地塞米松和抗 VEGF 治疗对炎症性角膜新生血管模型的早期影响。
Exp Eye Res. 2014 Aug;125:118-27. doi: 10.1016/j.exer.2014.06.006. Epub 2014 Jun 13.
4
[Current treatments for corneal neovascularization].[角膜新生血管的当前治疗方法]
J Fr Ophtalmol. 2015 Dec;38(10):996-1008. doi: 10.1016/j.jfo.2015.09.006. Epub 2015 Oct 29.
5
Treatments for corneal neovascularization: a review.角膜新生血管治疗：综述。
Cornea. 2011 Aug;30(8):927-38. doi: 10.1097/ICO.0b013e318201405a.
6
Corneal neovascularization: updates on pathophysiology, investigations & management.角膜新生血管化：病理生理学、检查及治疗的最新进展
Rom J Ophthalmol. 2019 Jan-Mar;63(1):15-22.
7
Recent drug therapies for corneal neovascularization.角膜新生血管的近期药物治疗方法。
Chem Biol Drug Des. 2017 Nov;90(5):653-664. doi: 10.1111/cbdd.13018. Epub 2017 Jun 21.
8
Corneal neovascularization.角膜新生血管。
Exp Eye Res. 2021 Jan;202:108363. doi: 10.1016/j.exer.2020.108363. Epub 2020 Nov 19.
9
Gene-based antiangiogenic applications for corneal neovascularization.基因靶向抗血管生成在角膜新生血管中的应用。
Surv Ophthalmol. 2018 Mar-Apr;63(2):193-213. doi: 10.1016/j.survophthal.2017.10.006. Epub 2017 Nov 15.
10
Management of corneal neovascularization: Current and emerging therapeutic approaches.角膜新生血管的治疗管理：当前和新兴的治疗方法。
Indian J Ophthalmol. 2024 May 1;72(Suppl 3):S354-S371. doi: 10.4103/IJO.IJO_3043_23. Epub 2024 Apr 20.
引用本文的文献
1
miR-497 knockout aggravates alkali burn-induced corneal neovascularization via VEGFA and FGF2 pathways in mice models.在小鼠模型中，miR-497基因敲除通过VEGFA和FGF2途径加重碱烧伤诱导的角膜新生血管形成。
Int Ophthalmol. 2025 Aug 12;45(1):328. doi: 10.1007/s10792-025-03691-3.
2
Effects of Dual Inhibition of VEGF-A and Angpt-2 on Angiogenesis and Lymphangiogenesis in an Alkali-Induced Corneal Injury Model.在碱诱导的角膜损伤模型中，VEGF-A和Angpt-2双重抑制对血管生成和淋巴管生成的影响。
Genes Cells. 2025 Jul;30(4):e70035. doi: 10.1111/gtc.70035.
3
Long-lasting comfort ocular surface drug delivery by in situ formation of an adhesive lubricative Janus nanocoating.通过原位形成粘性润滑性 Janus 纳米涂层实现长效舒适的眼表药物递送
Sci Adv. 2025 Mar 7;11(10):eads0282. doi: 10.1126/sciadv.ads0282.
4
Navigating the path to corneal healing success and challenges: a comprehensive overview.探索角膜愈合成功之路与挑战：全面概述
Eye (Lond). 2025 Apr;39(6):1047-1055. doi: 10.1038/s41433-025-03619-2. Epub 2025 Feb 12.
5
Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.用于治疗眼表化学伤的纳米技术进展：眼科进展反思
Adv Sci (Weinh). 2025 Feb;12(6):e2407340. doi: 10.1002/advs.202407340. Epub 2025 Jan 4.
6
Research progress on the correlation between corneal neovascularization and lymphangiogenesis (Review).角膜新生血管与淋巴管生成相关性的研究进展（综述）
Mol Med Rep. 2025 Feb;31(2). doi: 10.3892/mmr.2024.13412. Epub 2024 Dec 5.
7
Anterior Segment Optical Coherence Tomography Angiography: A Review of Applications for the Cornea and Ocular Surface.眼前节光学相干断层扫描血管造影：角膜和眼表面应用的综述。
Medicina (Kaunas). 2024 Sep 28;60(10):1597. doi: 10.3390/medicina60101597.
8
Sustained and Efficient Delivery of Antivascular Endothelial Growth Factor by the Adeno-associated Virus for the Treatment of Corneal Neovascularization: An Outlook for Its Clinical Translation.腺相关病毒持续高效递送抗血管内皮生长因子治疗角膜新生血管：临床转化前景
J Ophthalmol. 2024 Sep 9;2024:5487973. doi: 10.1155/2024/5487973. eCollection 2024.
9
Preparation and in vivo and ex vivo studies of sirolimus nano-in-situ gel ophthalmic formulation.西罗莫司纳米原位凝胶眼用制剂的制备及体内和体外研究
J Nanobiotechnology. 2024 Jul 16;22(1):417. doi: 10.1186/s12951-024-02668-1.
10
A SU6668 pure nanoparticle-based eyedrops: toward its high drug Accumulation and Long-time treatment for corneal neovascularization.SU6668 纯纳米粒子眼药水：实现高药物蓄积和长时间治疗角膜新生血管的新途径。
J Nanobiotechnology. 2024 May 27;22(1):290. doi: 10.1186/s12951-024-02510-8.
本文引用的文献
1
UV light crosslinking regresses mature corneal blood and lymphatic vessels and promotes subsequent high-risk corneal transplant survival.紫外线交联可使成熟的角膜血管和淋巴管退化，并促进随后高危角膜移植的存活。
Am J Transplant. 2018 Dec;18(12):2873-2884. doi: 10.1111/ajt.14874. Epub 2018 May 26.
2
Fine Needle-Diathermy Regresses Pathological Corneal (Lymph)Angiogenesis and Promotes High-Risk Corneal Transplant Survival.细针电凝术使病理性角膜（淋巴）血管生成消退，并促进高危角膜移植存活。
Sci Rep. 2018 Apr 9;8(1):5707. doi: 10.1038/s41598-018-24037-3.
3
Cornea-Derived Mesenchymal Stromal Cells Therapeutically Modulate Macrophage Immunophenotype and Angiogenic Function.角膜来源的间充质基质细胞治疗性调节巨噬细胞免疫表型和血管生成功能。
Stem Cells. 2018 May;36(5):775-784. doi: 10.1002/stem.2781. Epub 2018 Jan 27.
4
Selective IKK2 inhibitor IMD0354 disrupts NF-κB signaling to suppress corneal inflammation and angiogenesis.选择性 IKK2 抑制剂 IMD0354 破坏 NF-κB 信号通路以抑制角膜炎症和血管生成。
Angiogenesis. 2018 May;21(2):267-285. doi: 10.1007/s10456-018-9594-9. Epub 2018 Jan 13.
5
Effectiveness of photodynamic therapy with verteporfin combined with intrastromal bevacizumab for corneal neovascularization in Stevens-Johnson syndrome.维替泊芬光动力疗法联合基质内注射贝伐单抗治疗史蒂文斯-约翰逊综合征角膜新生血管的疗效
Int Ophthalmol. 2019 Jan;39(1):55-62. doi: 10.1007/s10792-017-0786-x. Epub 2017 Dec 18.
6
Therapeutic approaches for corneal neovascularization.角膜新生血管的治疗方法。
Eye Vis (Lond). 2017 Dec 10;4:28. doi: 10.1186/s40662-017-0094-6. eCollection 2017.
7
Label-Free In Vivo Imaging of Corneal Lymphatic Vessels Using Microscopic Optical Coherence Tomography.使用显微光学相干断层扫描技术对角膜淋巴管进行无标记活体成像。
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5880-5886. doi: 10.1167/iovs.17-22286.
8
Photodynamic Therapy Leads to Time-Dependent Regression of Pathologic Corneal (Lymph) Angiogenesis and Promotes High-Risk Corneal Allograft Survival.光动力疗法可导致病理性角膜（淋巴）血管生成随时间推移而消退，并促进高危角膜移植存活。
Invest Ophthalmol Vis Sci. 2017 Nov 1;58(13):5862-5869. doi: 10.1167/iovs.17-22904.
9
Gene-based antiangiogenic applications for corneal neovascularization.基因靶向抗血管生成在角膜新生血管中的应用。
Surv Ophthalmol. 2018 Mar-Apr;63(2):193-213. doi: 10.1016/j.survophthal.2017.10.006. Epub 2017 Nov 15.
10
Corneal Mesenchymal Stromal Cells Are Directly Antiangiogenic via PEDF and sFLT-1.角膜间充质基质细胞通过色素上皮衍生因子（PEDF）和可溶性血管内皮生长因子受体-1（sFLT-1）直接发挥抗血管生成作用。
Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5507-5517. doi: 10.1167/iovs.17-22680.
Zotero 插件